-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Hold on Regeneron Pharmaceuticals, Lowers Price Target to $150

Benzinga·04/17/2025 12:33:51
Listen to the news
Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Hold and lowers the price target from $170 to $150.